S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Forecast, Price & News

$2.43
+0.05 (+2.10%)
(As of 06/6/2023 ET)
Compare
Today's Range
$2.35
▼
$2.45
50-Day Range
$1.67
▼
$3.67
52-Week Range
$1.15
▼
$3.84
Volume
785,336 shs
Average Volume
1.17 million shs
Market Capitalization
$88.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
332.1% Upside
$10.50 Price Target
Short Interest
Healthy
4.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.13 to ($0.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

703rd out of 981 stocks

Pharmaceutical Preparations Industry

337th out of 469 stocks

See Top Rated MarketRank™ Stocks Here

SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Stock News Headlines

May 19, 2023 | seekingalpha.com
Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
May 19, 2023 | benzinga.com
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
June 6, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
May 16, 2023 | americanbankingnews.com
Q3 2023 Earnings Estimate for SCYNEXIS, Inc. Issued By Brookline Capital Management (NASDAQ:SCYX)
May 14, 2023 | americanbankingnews.com
Equities Analysts Issue Forecasts for SCYNEXIS, Inc.'s Q2 2023 Earnings (NASDAQ:SCYX)
May 12, 2023 | marketwatch.com
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME(R) (Ibrexafungerp Tablets)
May 12, 2023 | msn.com
SCYNEXIS: Q1 Earnings Insights
May 12, 2023 | finance.yahoo.com
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
June 6, 2023 | MarketBeat Internal (Ad)
Your Ultimate Investment Research Platform
MarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more.
May 12, 2023 | finance.yahoo.com
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
May 11, 2023 | finanznachrichten.de
Scynexis: SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 | washingtonpost.com
Scynexis: Q1 Earnings Snapshot
May 8, 2023 | finance.yahoo.com
SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48%
April 27, 2023 | americanbankingnews.com
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update
April 13, 2023 | finance.yahoo.com
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
April 13, 2023 | 247wallst.com
Unusual Call Option Trade in Scynexis Worth $37.65K
April 12, 2023 | msn.com
Unusual Call Option Trade in SCYNEXIS (SCYX) Worth $37.65K
April 12, 2023 | americanbankingnews.com
SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to Sell
April 11, 2023 | finance.yahoo.com
We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon
April 7, 2023 | americanbankingnews.com
SCYNEXIS, Inc. (NASDAQ:SCYX) to Post Q1 2023 Earnings of ($0.28) Per Share, Brookline Capital Management Forecasts
April 6, 2023 | americanbankingnews.com
Guggenheim Raises SCYNEXIS (NASDAQ:SCYX) Price Target to $9.00
April 5, 2023 | americanbankingnews.com
SCYNEXIS (NASDAQ:SCYX) Rating Reiterated by LADENBURG THALM/SH SH
April 5, 2023 | americanbankingnews.com
SCYNEXIS (NASDAQ:SCYX) Stock Rating Upgraded by StockNews.com
April 3, 2023 | markets.businessinsider.com
SCYNEXIS (SCYX) Receives a Buy from Ladenburg Thalmann & Co.
March 31, 2023 | finance.yahoo.com
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
March 31, 2023 | americanbankingnews.com
SCYNEXIS (NASDAQ:SCYX) Price Target Raised to $10.00 at Maxim Group
March 22, 2023 | finance.yahoo.com
SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses
See More Headlines

SCYX Price History

SCYX Company Calendar

Last Earnings
3/31/2023
Today
6/06/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
CUSIP
N/A
CIK
1178253
Web
www.scynexis.com
Phone
(201) 884-5485
Fax
201-884-5490
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+339.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
18.38
P/E Growth
N/A
Net Income
$-62,810,000.00
Net Margins
-1,648.61%
Pretax Margin
-1,648.61%
Return on Equity
-875.77%
Return on Assets
-77.67%

Debt

Debt-to-Equity Ratio
14.04
Current Ratio
1.31
Quick Ratio
1.29

Sales & Book Value

Annual Sales
$5.09 million
Price / Sales
17.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
23.90

Miscellaneous

Outstanding Shares
36,520,000
Free Float
34,925,000
Market Cap
$87.28 million
Optionable
Optionable
Beta
2.13

Key Executives

  • Mr. David Gonzalez Angulo M.D. (Age 58)
    CEO, Pres & Director
    Comp: $631.69k
  • Mr. Scott Sukenick J.D. (Age 45)
    Chief Legal Officer & Corp. Sec.
    Comp: $542.05k
  • Mr. Ivor Macleod CPA (Age 62)
    M.B.A., Chief Financial Officer
  • Debbie Etchison
    Exec. Director of Communications
  • Ms. Daniella Gigante
    VP of HR

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price targets for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 339.3% from the stock's current price.
View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2023?

SCYNEXIS's stock was trading at $1.56 on January 1st, 2023. Since then, SCYX stock has increased by 53.2% and is now trading at $2.39.
View the best growth stocks for 2023 here.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SCYX earnings forecast.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Friday, March, 31st. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.21. The firm had revenue of $1.52 million for the quarter, compared to analysts' expectations of $1.28 million. SCYNEXIS had a negative trailing twelve-month return on equity of 875.77% and a negative net margin of 1,648.61%.

When did SCYNEXIS's stock split?

Shares of SCYNEXIS reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.10%), AIGH Capital Management LLC (3.17%), Stonepine Capital Management LLC (1.23%), BlackRock Inc. (1.04%), D.A. Davidson & CO. (0.91%) and AMH Equity Ltd (0.75%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.39.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $87.28 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -